198 related articles for article (PubMed ID: 37290653)
1. Plasma concentrations of per- and polyfluoroalkyl substances in pregnancy and breastfeeding duration in Project Viva.
Rokoff LB; Wallenborn JT; Harris MH; Rifas-Shiman SL; Criswell R; Romano ME; Young JG; Calafat AM; Oken E; Sagiv SK; Fleisch AF
Sci Total Environ; 2023 Sep; 891():164724. PubMed ID: 37290653
[TBL] [Abstract][Full Text] [Related]
2. Prenatal exposure to per- and polyfluoroalkyl substances and maternal and neonatal thyroid function in the Project Viva Cohort: A mixtures approach.
Preston EV; Webster TF; Claus Henn B; McClean MD; Gennings C; Oken E; Rifas-Shiman SL; Pearce EN; Calafat AM; Fleisch AF; Sagiv SK
Environ Int; 2020 Jun; 139():105728. PubMed ID: 32311629
[TBL] [Abstract][Full Text] [Related]
3. Correlates of plasma concentrations of per- and poly-fluoroalkyl substances among reproductive-aged Black women.
Wise LA; Wesselink AK; Schildroth S; Calafat AM; Bethea TN; Geller RJ; Coleman CM; Fruh V; Claus Henn B; Botelho JC; Harmon QE; Thirkill M; Wegienka GR; Baird DD
Environ Res; 2022 Jan; 203():111860. PubMed ID: 34403666
[TBL] [Abstract][Full Text] [Related]
4. Plasma per- and polyfluoroalkyl substance mixtures during pregnancy and duration of breastfeeding in the New Hampshire birth cohort study.
Romano ME; Gallagher LG; Price G; Crawford KA; Criswell R; Baker E; Botelho JC; Calafat AM; Karagas MR
Int J Hyg Environ Health; 2024 May; 258():114359. PubMed ID: 38521049
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Postpartum Health in Project Viva: A Prospective Cohort.
Mitro SD; Sagiv SK; Fleisch AF; Jaacks LM; Williams PL; Rifas-Shiman SL; Calafat AM; Hivert MF; Oken E; James-Todd TM
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3415-26. PubMed ID: 32620010
[TBL] [Abstract][Full Text] [Related]
6. Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort.
Preston EV; Hivert MF; Fleisch AF; Calafat AM; Sagiv SK; Perng W; Rifas-Shiman SL; Chavarro JE; Oken E; Zota AR; James-Todd T
Environ Int; 2022 Jul; 165():107335. PubMed ID: 35696844
[TBL] [Abstract][Full Text] [Related]
7. Maternal Plasma per- and Polyfluoroalkyl Substance Concentrations in Early Pregnancy and Maternal and Neonatal Thyroid Function in a Prospective Birth Cohort: Project Viva (USA).
Preston EV; Webster TF; Oken E; Claus Henn B; McClean MD; Rifas-Shiman SL; Pearce EN; Braverman LE; Calafat AM; Ye X; Sagiv SK
Environ Health Perspect; 2018 Feb; 126(2):027013. PubMed ID: 29488882
[TBL] [Abstract][Full Text] [Related]
8. Associations of Prenatal Per- and Polyfluoroalkyl Substance (PFAS) Exposures with Offspring Adiposity and Body Composition at 16-20 Years of Age: Project Viva.
Zhang M; Rifas-Shiman SL; Aris IM; Fleisch AF; Lin PD; Nichols AR; Oken E; Hivert MF
Environ Health Perspect; 2023 Dec; 131(12):127002. PubMed ID: 38054701
[TBL] [Abstract][Full Text] [Related]
9. Prenatal and Childhood Per- and Polyfluoroalkyl Substance (PFAS) Exposures and Blood Pressure Trajectories From Birth to Late Adolescence in a Prospective US Prebirth Cohort.
Zhang M; Aris IM; Lin PD; Rifas-Shiman SL; Brady TM; James-Todd T; Oken E; Hivert MF
J Am Heart Assoc; 2023 Sep; 12(17):e030760. PubMed ID: 37642023
[TBL] [Abstract][Full Text] [Related]
10. Associations of perfluoroalkyl and polyfluoroalkyl substances (PFAS) and PFAS mixtures with adipokines in midlife women.
Ding N; Karvonen-Gutierrez CA; Herman WH; Calafat AM; Mukherjee B; Park SK
Int J Hyg Environ Health; 2021 Jun; 235():113777. PubMed ID: 34090141
[TBL] [Abstract][Full Text] [Related]
11. Per- and polyfluoroalkyl substances and blood pressure in pre-diabetic adults-cross-sectional and longitudinal analyses of the diabetes prevention program outcomes study.
Lin PD; Cardenas A; Hauser R; Gold DR; Kleinman KP; Hivert MF; Calafat AM; Webster TF; Horton ES; Oken E
Environ Int; 2020 Apr; 137():105573. PubMed ID: 32088543
[TBL] [Abstract][Full Text] [Related]
12. Maternal serum per- and polyfluoroalkyl substances during pregnancy and breastfeeding duration.
Friedman C; Dabelea D; Keil AP; Adgate JL; Glueck DH; Calafat AM; Starling AP
Environ Epidemiol; 2023 Aug; 7(4):e260. PubMed ID: 37545807
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends and determinants of serum concentrations of per- and polyfluoroalkyl substances among Northern California mothers with a young child, 2009-2016.
Kim K; Bennett DH; Calafat AM; Hertz-Picciotto I; Shin HM
Environ Res; 2020 Jul; 186():109491. PubMed ID: 32361076
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Changes in Maternal Serum Concentrations of Per- and Polyfluoroalkyl Substances from Pregnancy to Two Years Postpartum.
Oh J; Bennett DH; Tancredi DJ; Calafat AM; Schmidt RJ; Hertz-Picciotto I; Shin HM
Environ Sci Technol; 2022 Aug; 56(16):11449-11459. PubMed ID: 35904360
[TBL] [Abstract][Full Text] [Related]
15. Higher serum concentrations of PFAS among pesticide exposed female greenhouse workers.
Andersen HR; Grandjean P; Main KM; Jensen TK; Nielsen F
Int J Hyg Environ Health; 2024 Jan; 255():114292. PubMed ID: 37952389
[TBL] [Abstract][Full Text] [Related]
16. Prenatal and childhood exposure to per- and polyfluoroalkyl substances (PFAS) and child executive function and behavioral problems.
Harris MH; Oken E; Rifas-Shiman SL; Calafat AM; Bellinger DC; Webster TF; White RF; Sagiv SK
Environ Res; 2021 Nov; 202():111621. PubMed ID: 34237332
[TBL] [Abstract][Full Text] [Related]
17. Dietary characteristics associated with plasma concentrations of per- and polyfluoroalkyl substances among adults with pre-diabetes: Cross-sectional results from the Diabetes Prevention Program Trial.
Lin PD; Cardenas A; Hauser R; Gold DR; Kleinman KP; Hivert MF; Fleisch AF; Calafat AM; Sanchez-Guerra M; Osorio-Yáñez C; Webster TF; Horton ES; Oken E
Environ Int; 2020 Apr; 137():105217. PubMed ID: 32086073
[TBL] [Abstract][Full Text] [Related]
18. Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and associations with attention-deficit/hyperactivity disorder and autism spectrum disorder in children.
Skogheim TS; Weyde KVF; Aase H; Engel SM; Surén P; Øie MG; Biele G; Reichborn-Kjennerud T; Brantsæter AL; Haug LS; Sabaredzovic A; Auyeung B; Villanger GD
Environ Res; 2021 Nov; 202():111692. PubMed ID: 34293314
[TBL] [Abstract][Full Text] [Related]
19. Associations of prenatal and postnatal exposure to perfluoroalkyl substances with pubertal development and reproductive hormones in females and males: The HOME study.
Liu Y; Calafat AM; Chen A; Lanphear BP; Jones NY; Cecil KM; Rose SR; Yolton K; Buckley JP; Braun JM
Sci Total Environ; 2023 Sep; 890():164353. PubMed ID: 37225096
[TBL] [Abstract][Full Text] [Related]
20. Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women.
Brantsæter AL; Whitworth KW; Ydersbond TA; Haug LS; Haugen M; Knutsen HK; Thomsen C; Meltzer HM; Becher G; Sabaredzovic A; Hoppin JA; Eggesbø M; Longnecker MP
Environ Int; 2013 Apr; 54():74-84. PubMed ID: 23419425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
